Epithalon

Epithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, designed by Russian researcher Vladimir Khavinson to mimic an older bovine pineal extract called Epithalamin. It is best known for a claimed telomerase-activating, anti-aging effect, but that claim rests almost entirely on cell-culture work from Khavinson’s own laboratory, with a single independent 2025 in vitro replication. Every human study reporting a clinical benefit comes from that same research network, used the older Epithalamin extract rather than the synthetic peptide sold today, and has never been independently reproduced or registered on ClinicalTrials.gov. It has no approved medical use anywhere.

Ask about Epitalon

Research snapshot

CategoryCurrent information
Peptide categorySynthetic tetrapeptide (pineal-derived)
Primary research interestTelomerase activation / cellular senescence, circadian and melatonin regulation, longevity
Highest available evidencePublished human observational research (older Epithalamin extract), plus one small randomized trial of the synthetic tetrapeptide with a melatonin-metabolite outcome, as described in the FDA briefing document
Human research availableLimited: mostly the older extract; one small trial of the synthetic form (sublingual, 75 healthy women, no sleep outcome)
Development statusNot in formal pharmaceutical development; researched and marketed as Epitalon/Epithalon by Khavinson’s network and research-peptide vendors
Regulatory statusNo FDA or EMA approval; no ClinicalTrials.gov registration under any spelling. FDA staff weighed against adding it to the 503A bulks list; an advisory committee recommended it 7-5-1 on 24 July 2026 (non-binding); named in a draft HHS 503A enforcement-discretion policy published 30 Oct 2026 (not approval)

Technical identity

Technical propertyInformation
Primary nameEpithalon (Epitalon)
Alternative namesEpitalone, Epithalone, AEDG peptide/tetrapeptide, Khavinson peptide; commonly confused with Epithalamin, the older bovine pineal extract it was designed to mimic
Peptide sequenceAla-Glu-Asp-Gly (H-Ala-Glu-Asp-Gly-OH)
Amino-acid length4 residues
Molecular formulaC14H22N4O9
Molecular weight390.35 g/mol
CAS Registry Number307297-39-8
PubChem CID219042
Chemical modificationsNone; unmodified linear tetrapeptide
Peptide classPineal bioregulator peptide
Primary biological targetProposed telomerase (hTERT) upregulation and pineal/melatonin regulation; mechanism not established in vivo in humans
Developer or originatorVladimir Khavinson and collaborators (St. Petersburg Institute of Bioregulation and Gerontology)
Development statusNot in formal clinical development; no registered trials

What it is

Epithalon (also spelled Epitalon, and sometimes Epithalone/Epitalone) is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, written Ala-Glu-Asp-Gly or AEDG. It was designed and first studied by the Russian researcher Vladimir Khavinson, of the St. Petersburg Institute of Bioregulation and Gerontology, to reproduce the biological activity of an older preparation called Epithalamin (also Epithalamine), a mixed polypeptide extract originally isolated from bovine pineal gland tissue. Epithalamin is a complex extract; Epithalon/Epitalon is the single defined tetrapeptide built to imitate part of its activity, and a later Khavinson-group paper reported detecting the AEDG sequence within the pineal polypeptide complex itself by mass spectrometry. The two names are frequently used interchangeably online and in parts of the older Russian literature, but they are not the same material, and that distinction matters for reading the evidence below: the human studies most often cited for this compound tested Epithalamin, the extract, not the synthetic tetrapeptide sold today as Epithalon or Epitalon.

The compound has no approved medical use anywhere reviewed for this entry, is not the active ingredient of any marketed drug, and has no entry on ClinicalTrials.gov under any spelling searched, including Epitalon, Epithalon, Epithalone, and the chemical name “AEDG peptide.” It is sold by research-chemical vendors under a “research use only” framing and circulates in online longevity and anti-aging communities on the strength of a handful of small studies and a widely repeated claim about telomerase activation, discussed in the mechanism section below.

Mechanism, and a caution about where the evidence for it comes from

Melatonin and circadian rhythm

The most consistently reported effect, across both animal and small human studies, involves the pineal gland’s own hormone, melatonin. In old rhesus monkeys, Epitalon was reported to raise basal night-time melatonin and improve glucose-tolerance-test dynamics, with no effect seen in young monkeys, an animal study. In small groups of elderly human subjects, researchers reported that a course of Epithalamin tended to raise night-time plasma melatonin in people whose baseline pineal output was already low, while tending to lower it slightly in those with normal baseline function, which the authors described as a “normalizing” rather than simply stimulant effect. A 2024 narrative review from the same research group extended this to a proposed cellular mechanism, stating that the peptide affects circadian-clock gene expression (citing genes such as Cry2, AANAT, ASMT and CLOCK) measured in buccal epithelium cells, and reduces expression of certain apoptosis-related proteins, but that review summarizes the same institute’s own prior work rather than reporting new independently generated data.

The telomerase claim: what it is actually based on

Epithalon’s reputation rests heavily on a claim that it activates telomerase, the enzyme that rebuilds the protective caps (telomeres) on the ends of chromosomes, and by extension on the idea that it might slow cellular aging. That claim needs to be stated carefully, because of what actually supports it. The original findings came from Khavinson’s own laboratory: in 2003, the group reported that adding Epithalon to telomerase-negative human fetal fibroblast cell cultures induced expression of the enzyme’s catalytic subunit, telomerase activity, and telomere elongation. A 2004 follow-up from the same lab, in the same journal, reported that peptide-treated aging fibroblasts underwent roughly ten additional cell divisions before reaching replicative senescence compared with untreated cells, which the authors described as overcoming the Hayflick limit. Both of these are in vitro, cell-culture findings from a single research group, and no independent verification of either was described at the time.

The first genuinely independent check on this claim came only in 2025, from a UK academic group at Brunel University London’s Centre for Genome Engineering and Maintenance, unconnected to Khavinson’s network. Treating breast cancer cell lines and normal epithelial and fibroblast cells with Epitalon, they reported dose-dependent telomere lengthening in normal cells through telomerase (hTERT) upregulation, and telomere extension in the cancer cell lines through a different pathway, called Alternative Lengthening of Telomeres, that does not rely on telomerase. This study, published in Biogerontology (with a subsequent correction), is the one clearly independent piece of evidence located for this entry that supports part of the mechanistic story, and it deserves to be stated plainly as such. It is still cell-culture work, not a human or even a whole-animal finding, and it also identified a mechanistic complication, activation of a cancer-associated telomere-lengthening pathway in the cancer lines, that was not part of the original claim. No study located for this entry has measured telomerase activity or telomere length in blood or tissue taken from a living human being who received Epithalon or Epitalon. The signature claim behind this compound’s reputation has never been shown to occur inside a treated person.

Other proposed mechanisms

Secondary claims in the literature include effects on gene expression tied to interleukin-2 and thymocyte activity, effects on enzymes including acetylcholinesterase and telomerase, and effects on retinal cell proliferation in culture and in a rat model of hereditary retinal degeneration. Each of these traces back to the same research network, and in at least two cases, a claimed effect on the CDC2 cell-cycle gene, and the specific interleukin-2/thymocyte study referenced in review articles, a direct search for the primary paper returned no result, meaning the underlying study could not be located or checked for design or sample size for this entry.

What dosage information circulates?

Figures in this table summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Elderly cohort courses (Epithalamin extract, not the synthetic tetrapeptide)Intramuscular injection (extract)No stated milligram amount for the active tetrapeptide; extract given as a periodic coursePeriodic coursesMulti-year cohort follow-upPublished human observational research, single research network (Khavinson and collaborators)
General anti-aging / longevity protocol (synthetic Epitalon)Subcutaneous injection most commonly described; oral or sublingual use also sometimes described, which is inconsistent with a peptide of this class surviving first-pass metabolismCommonly described in the low-single-digit milligram range per dayDaily during a cycleShort cycles, commonly around 10-20 days, repeated once or twice a yearCommunity / vendor reported
Melatonin metabolite levels in healthy women aged 40 to 50 (synthetic epitalon)Sublingual0.5 mg per dayNot stated in the FDA summaryNot stated in the FDA summaryPublished human clinical trial, small (75 women), as described in the FDA briefing document; not a sleep outcome

The one human trial of the synthetic peptide that FDA identified is a randomized, placebo-controlled study (Ivko et al., 2021) in 75 healthy women aged 40 to 50. The dose was 0.5 mg a day, taken sublingually (under the tongue). It measured a melatonin metabolite, not sleep, and FDA noted it was short, small and not clearly blinded. FDA found no pharmacokinetic data for epitalon. It also noted that some wellness websites cite 5 to 10 mg a day, and that one monkey study used 2 µg/kg intramuscularly. Those are the figures FDA reported, and none is a validated dose for any use. The paper could not be located in PubMed, so it is the Ivko paper in PubMed, so it is described here as FDA summarizes it.

Apart from one small sublingual trial (0.5 mg a day, melatonin-metabolite outcome, as described in the FDA briefing document), no study located for this entry reports a human dose, injection route, or treatment duration for the synthetic AEDG tetrapeptide itself. The human studies that exist used Epithalamin, the older pineal extract, given as periodic courses with no stated milligram amount, so there is no established human figure for the synthetic peptide against which the commonly circulated 10-20 day, low-milligram protocol can be checked. Vendors and community sources sometimes describe circulating protocols as echoing the “course” structure of the Khavinson human studies, but that equivalence is not supported by the literature.

Potential benefits and research applications

Telomere maintenance, a claim built almost entirely on cell-culture work

What is being investigated: whether the peptide can activate telomerase and lengthen telomeres, the protective caps on chromosome ends whose shortening is linked to cellular aging. How the effect might occur: by inducing expression of telomerase’s catalytic subunit in cells that were not producing it. Evidence: the original 2003 to 2004 findings from Khavinson’s own lab, and one independent 2025 replication from a UK academic group reporting dose-dependent telomere lengthening in cultured human cells. Strength: has been shown in cell culture; has not been established in a living human being. Limitation: no study located for this entry has measured telomerase activity or telomere length in blood or tissue from a treated person, and the independent replication also found a cancer-associated telomere-lengthening pathway activated in cancer cell lines, a complication not part of the original claim.

Melatonin and circadian rhythm normalization

What is being investigated: whether the peptide restores normal night-time melatonin secretion in older adults with reduced pineal function. How the effect might occur: through effects on circadian-clock gene expression proposed by the treating research group. Evidence: small human studies reported a “normalizing” pattern, raising melatonin in subjects with low baseline output and slightly lowering it in those with normal function; an animal study in old rhesus monkeys reported similar effects with improved glucose-tolerance dynamics. Strength: has been reported in small studies from a single research network; has not been independently replicated. Limitation: the human studies used Epithalamin, the older pineal extract, not the synthetic tetrapeptide sold today, and none disclosed a placebo arm or blinding method in the material reviewed for this entry.

Reduced mortality and illness in elderly cohorts, reported only by the treating network

What is being investigated: whether periodic Epithalamin courses reduce all-cause mortality, cardiovascular illness, and respiratory illness in older adults. How the effect might occur: no specific mechanism for a mortality benefit is proposed beyond the general geroprotector framing. Evidence: Korkushko and Khavinson’s own studies report reductions in mortality and illness incidence, in some cases severalfold, across cohorts followed for six to fifteen years. Strength: has been reported anecdotally by the same research network across multiple papers; has not been established by any independent group. Limitation: every study reporting these figures was authored by Khavinson, Korkushko, or their direct collaborators, none is registered on ClinicalTrials.gov, and most do not state a blinding method, placebo arm, or sample size in the material reviewed.

What the human evidence actually shows

A single research network, not independent replication

Every human study located for this entry that reports an efficacy or clinical outcome for Epithalon, Epitalon, or Epithalamin comes from Vladimir Khavinson himself, from his long-term collaborators Oleg Korkushko and Valentina Shatilo at the Institute of Gerontology in Kiev, or from other closely affiliated co-authors at the same St. Petersburg institute. No independently authored human clinical trial of any of these names was found. Several of the human studies used Epithalamin, the polypeptide pineal extract given as periodic treatment “courses,” rather than a stated milligram dose of the synthetic AEDG tetrapeptide, an important distinction the rest of this section preserves.

A 2006 report described a study following elderly patients with coronary disease and signs of accelerated cardiovascular aging over twelve years, comparing those given Epithalamin against a control group, and reported 28 percent lower overall mortality and roughly half the cardiovascular mortality and cardiovascular/respiratory illness incidence in the treated group. A 2011 report from the same group followed 39 coronary patients given Epithalamin alongside standard therapy against 40 controls over three years, with fifteen-year mortality follow-up, and reported decelerated cardiovascular aging markers and significantly lower mortality in the treated group. A 2004 report from the same authors measured circadian plasma melatonin in healthy elderly subjects before and after a course of Epithalamin and reported the normalizing pattern described above. A 2003 report by Khavinson and a co-author followed 266 elderly and older adults for six to eight years, comparing groups given a thymus-derived peptide (Thymalin), Epithalamin, both, or neither, and reported reductions of roughly half to two-thirds in acute respiratory illness and reductions in mortality ranging from 1.6-fold to as much as 4.1-fold in a subgroup given both peptides annually for six years.

These numbers sound substantial, and the entry states them because they are what the papers report, but every one of these studies is small to moderate in size (39 versus 40 patients in one case; 266 total split across several arms in the largest), every one is described in its own abstract without a stated blinding method or placebo arm for most of them, none was located with a publicly accessible protocol, and none is registered on ClinicalTrials.gov or any comparable registry. One study in this set, examining Epithalamin in women with heart disease and hypertension, does carry a double-blind designation in its indexed record, but its detailed methodology was not retrieved for this entry. Read only from what could be gathered here, a neutral reviewer would have to describe this body of work as a single research network’s multi-decade, mostly open-label program, reported in Russian regional gerontology journals and one editorially unusual international journal, that has not been reproduced by any outside group. No study in this set gives a human dose, injection route, or treatment duration for the synthetic Epitalon tetrapeptide itself, only for Epithalamin, the different, older preparation.

Safety

Structured human safety data for this compound are essentially absent. A direct search for toxicity or adverse-event reporting on Epitalon returned no results. What exists instead is scattered through the efficacy papers described above: one review from the treating research group itself states that the pineal peptide preparations raise melatonin “with no side effects,” which is an assertion by the group running the studies, not a systematically collected adverse-event dataset, and should not be read as an established safety finding. No study located for this entry reports a structured adverse-event table, a count of dropouts due to toxicity, routine laboratory safety monitoring such as liver or kidney function tracking, or a maximum tolerated human dose. No immunogenicity data, whether the body forms antibodies against the peptide, a documented concern for other synthetic peptides in this project’s other entries, were found for Epithalon in humans. No long-term human safety follow-up beyond the mortality and illness counts reported by the treating group itself, discussed above, was located. Formal animal toxicology, of the repeat-dose, genotoxicity or reproductive-toxicity kind typically run before human dosing, was likewise not located; the animal papers that exist measure physiological endpoints like melatonin and glucose, not a toxicology program.

Cancer risk in either direction is unresolved. Rodent breast-cancer models have reported that Epithalamin and Epitalon inhibit mammary tumor development, and a separate line of more recent, unrelated research used Epitalon’s telomere-related activity as a tool to selectively target chemoresistant senescent cancer cells in mouse models, a specific laboratory application, not evidence of a general anti-cancer or pro-cancer effect in ordinary human use. No human cancer-outcome data of any kind exist for this compound. In short: this is a compound with almost no structured human safety record, marketed into a wellness and longevity audience that is unlikely to be monitored the way a clinical trial participant would be.

Regulatory status

In the United States, epitalon was nominated for the 503A bulk drug substances list. FDA evaluated only insomnia and two forms, the free base (C14H22N4O9, 390.35 g/mol, CAS 307297-39-8) and the acetate salt (CAS 307297-40-1). FDA staff concluded the balance weighs against listing either form, citing no studies in people with insomnia, none using the proposed subcutaneous route, limited nonclinical safety data (no repeat-dose, reproductive or carcinogenicity studies), and immunogenicity and impurity concerns. FDA also noted that epitalon may activate telomerase, which raises carcinogenicity concerns (FDA briefing document).

On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 5 with one abstention to recommend adding it, against FDA staff (RAPS). The vote is non-binding, and a proposed rule, public comment and a final rule would have to come first. As of mid-August 2026 reporting, FDA had not acted on the vote. News reports on 7 to 8 October 2026 described administration plans for temporary sales of some unapproved peptides without naming them. HHS then published the notice summarized below on 30 October 2026.

On 28 October 2026 HHS announced a draft enforcement discretion policy for compounding certain peptides under section 503A. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496). Epitalon is one of six peptides named, listed as epitalon acetate, with subcutaneous or intramuscular use dispensed in intermittent courses as the routes in its Appendix B. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding it under 503A if conditions are met. These include a patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting, and the label “This is a compounded drug product. Not for resale.” In its notes HHS says limited controlled human exposure reported no side effects and that documented regimens are intermittent. It is a draft and is not binding on HHS or the public. It is not an FDA approval, it does not add Epitalon to the 503A bulks list, and it is not a rule. It does not bind state boards of pharmacy. HHS says it stays in place until each peptide is addressed in a final rule, and it can be withdrawn. It does not cover 503B outsourcing facilities. Comments close 13 November 2026. The notice adds no new trials, and the evidence assessment on this page, which rests mostly on the older extract Epithalamin, is unchanged. The full analysis of the HHS policy covers all six peptides. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.

Epithalon and Epitalon have no FDA approval and no EMA approval, and neither is the subject of any identified New Drug Application, Biologics License Application, or Marketing Authorisation Application in the US or EU. No FDA warning letter naming Epitalon or Epithalon specifically was located for this entry, though a 2026 pharmacy-compounding trade journal article discussed “Epitalon” by name alongside several other unapproved research peptides, including BPC-157, KPV, MOTS-c, Semax and TB-500 as part of a wider review of compounded research peptides, describing these compounds generally as promoted for a wide range of uses and examining the concerns raised during that review. What a specific Russian regulatory registration, category, or current status might be for Epitalon, Epithalon, or the older Epithalamin preparation could not be confirmed from the sources available for this entry, and no claim about Russian approval or supplement status should be read into this entry beyond that. Its status under the World Anti-Doping Agency’s Prohibited List was also not directly checked as part of this research and should not be assumed one way or the other.

Separately from any research literature, independent Belgian public-health forensic chemists identified the Epitalon tetrapeptide, using mass spectrometry, in two illegally sold pharmaceutical preparations marketed for cancer, old age, and retinitis pigmentosa. That finding, from analysts with no connection to Khavinson’s research network, confirms that the compound does circulate in unregulated and in at least one documented case illegal preparations, and that the material found matched what it was claimed to be, but it says nothing about whether that material is safe or effective for any use.

What the record gets wrong

Epithalon is, among the compounds covered on this site, one of the clearest cases where a compound’s online reputation has outrun its evidence base, and the gap is specific rather than vague. The “telomerase activation” and “reverses cellular aging” language attached to this peptide across wellness and longevity content typically cites the Khavinson group’s in vitro fibroblast work and the rodent lifespan studies without disclosing three things this entry has tried to state plainly: that the human “geroprotector” trials come entirely from one interlinked research network and were never independently replicated; that the telomerase claim itself has only ever been demonstrated in cultured cells, never in a living human being; and that the human clinical literature is largely about a different, older preparation, Epithalamin, the polypeptide extract, rather than about the synthetic AEDG tetrapeptide sold today under the Epithalon and Epitalon names. A single 2025 independent in vitro replication of part of the telomerase mechanism, from a UK academic group with no tie to Khavinson’s institute, is real and worth noting, but it changes none of this: it is still cell-culture work, and it does nothing to validate the human mortality and morbidity figures reported by the original research group. Until an outside laboratory or clinical group independently reproduces the human findings, and until someone establishes a human dose, route, and pharmacokinetic profile for the synthetic tetrapeptide itself rather than for the older pineal extract, this compound’s human evidence base should be read as a single research program’s decades-long report on its own work, not as an independently confirmed finding.

Frequently asked questions

What is Epithalon?

Epithalon (Epitalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, designed to mimic Epithalamin, an older bovine pineal extract. It has no approved medical use anywhere.

How does it work?

It is proposed to activate telomerase and normalize melatonin secretion, but the telomerase claim has only ever been demonstrated in cultured cells, never in a living human being.

What dosage has been studied?

Apart from one small sublingual trial (0.5 mg a day, melatonin-metabolite outcome, as described in the FDA briefing document), no study located for this entry reports a human dose, injection route, or treatment duration for the synthetic AEDG tetrapeptide itself. The human studies that exist used Epithalamin, the older pineal extract, given as periodic courses with no stated milligram amount.

What dosage commonly circulates online?

Vendor and community material commonly describes vials around 10 mg and short cycles of roughly 10 to 20 days, once or twice a year. No comparable published human dose for the synthetic tetrapeptide exists to check these figures against.

Has it been studied in humans?

Only by Vladimir Khavinson and his direct collaborators, using the older Epithalamin extract rather than the synthetic peptide sold today. No independently authored human clinical trial of Epithalon, Epitalon, or Epithalamin was found, and none is registered on ClinicalTrials.gov.

Does it actually reverse cellular aging?

That has not been established. The telomerase-activation claim behind this reputation comes from cell-culture work, with one independent 2025 replication also in cell culture. No study has measured telomerase activity or telomere length in a treated human being.

What side effects have been reported?

Structured human safety data are essentially absent. No adverse-event table, immunogenicity data, or maximum tolerated dose was located for this compound in humans.

Is it approved?

No. It has no FDA or EMA approval and no ClinicalTrials.gov registration under any spelling.

What remains unknown?

Whether the Khavinson network’s human findings would hold up under independent, blinded, placebo-controlled replication; whether the peptide activates telomerase in a living person; what human dose corresponds to the synthetic tetrapeptide itself; and whether it carries any cancer risk in either direction.

Bottom line

Epithalon is one of the clearest cases on this site where a compound’s online reputation has outrun its evidence base. The telomerase-activation and anti-aging language attached to it rests on cell-culture work from one Russian research group, with a single independent 2025 replication that is itself still cell-culture work. The human mortality and morbidity figures often cited alongside it come entirely from that same research network, describe a different, older preparation, and have never been reproduced by an outside group or registered on ClinicalTrials.gov. It has no approved use anywhere, no established human dose for the synthetic peptide, and essentially no structured human safety record.

Reported amounts and the evidence behind them: Epitalon dosage: what human studies used and what circulates online.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
General anti-aging / longevity protocolSubcutaneous (dominant pattern); oral/sublingual also describedLow-single-digit mg/day during a cycleDaily during a cycle10-20 day cycles, once or twice a year

What follows is a general pattern of how Epithalon/Epitalon is commonly described by research-peptide vendors and in longevity-community protocol material, based on general knowledge of this product category rather than on any vendor site checked, dated, or named in researching this entry. No specific figure below should be treated as confirmed current market data, and it is presented only as an aggregate pattern, not as something to follow.

Vials are commonly described in the low-milligram range, most often cited around 10 mg, sold as lyophilized powder with "research use only" framing. Circulating protocols commonly describe short cycles of roughly 10 to 20 days, once or twice a year, said to echo the "course" structure used in the Korkushko/Khavinson human studies, but as this entry's dosing section explains, those human courses were of Epithalamin, the older polypeptide extract, not a stated milligram dose of the synthetic Epitalon tetrapeptide, so any equivalence vendors draw between "the studied course" and a specific circulating milligram-per-day protocol is not supported by the human literature located for this entry. No comparable published human dose exists for the synthetic tetrapeptide against which to check these figures at all; unlike compounds where a circulating figure can be measured against an approved or trial dose, here there is simply no established figure on the other side of the comparison. No standard multi-peptide blend built around Epithalon under a market name was identified in researching this entry.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Sources

  1. Al-Dulaimi, Thomas, Matta & Roberts, Biogerontology, 2025. Independent (Brunel University London) in vitro study reporting dose-dependent telomere-length extension in normal human epithelial and fibroblast cells via hTERT/telomerase upregulation, and telomere extension in breast cancer cell lines (21NT, BT474) via Alternative Lengthening of Telomeres rather than telomerase, following Epitalon treatment. Cell-culture study, not human or in vivo. PMID 40908429
  2. Khavinson, Bondarev & Butyugov, 2003. Reported that Epithalon added to telomerase-negative human fetal fibroblast cell culture induced expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere elongation. In vitro, human cell culture, single research group. PMID 12937682
  3. Khavinson, Bondarev, Butyugov & Smirnova, 2004. Follow-up study reporting that Epithalon-treated aging human fibroblasts underwent roughly ten additional cell divisions (44 passages) before replicative senescence compared with untreated controls. In vitro, human cell culture, same research group as the 2003 paper. PMID 15455129
  4. Anisimov, Khavinson et al., 2001. Reported that subcutaneous synthetic Epithalon given to female CBA mice from 6 months of age until death slowed age-related loss of estrus function, decreased body temperature, decelerated free-radical processes, prolonged lifespan, and reduced spontaneous tumor incidence, with no effect on body weight, food consumption or behavior. Animal (mouse) study; no specific lifespan-extension percentage given in the abstract reviewed. PMID 11227856
  5. Goncharova, Vengerin, Khavinson & Lapin, 2005. In old (20-27 year) rhesus monkeys, Epitalon lowered basal glucose and insulin and increased basal night melatonin, and normalized glucose-tolerance-test dynamics, with no effect in young monkeys. Animal (non-human primate) study. PMID 15664732
  6. Korkushko, Khavinson, Shatilo & Antonyuk-Shcheglova, 2006. Described as a 12-year study in elderly subjects with coronary disease and accelerated cardiovascular aging, reporting 28% lower mortality, roughly 2-fold lower cardiovascular mortality, and roughly 2-fold lower cardiovascular failure and respiratory disease incidence in the Epithalamin-treated group versus control. Human study; no blinding, placebo arm, or sample size stated in the abstract reviewed; authored by the Khavinson/Korkushko research network. PMID 17426848
  7. Korkushko, Khavinson, Shatilo & Antonyk-Sheglova, 2011. Randomized comparative study of 39 coronary patients given Epithalamin plus basic therapy versus 40 control coronary patients on basic therapy alone over 3 years, with mortality follow-up described as 15 years; reported deceleration of cardiovascular aging markers and significantly lower mortality in the treated group. Human study, open-label as described in the abstract reviewed; same research network. PMID 22451889
  8. Korkushko, Khavinson, Shatilo & Magdich, 2004. Measured circadian plasma melatonin in healthy elderly subjects before and after a course of Epithalamin, reporting increased night-time melatonin in subjects with initially low pineal activity and a slight decrease in subjects with already-normal pineal function. Human study; no sample size, blinding, or placebo arm stated in the abstract reviewed; same research network. PMID 15452611
  9. Khavinson & Morozov, 2003. Followed 266 elderly and older persons for 6-8 years receiving Thymalin, Epithalamin, both, or control, reporting a 2.0- to 2.4-fold decrease in acute respiratory disease incidence, reduced incidence of several age-related conditions, and mortality reduced 1.6- to 4.1-fold depending on treatment arm. Human study; abstract reviewed gives no detail on randomization method, blinding, or placebo control; authored solely by Khavinson and a co-author. PMID 14523363
  10. Vanhee et al., Scientific Institute of Public Health (WIV-ISP), Brussels, 2014. Independent forensic-chemistry study identifying the Epitalon tetrapeptide by LC-MS(n) in two illegally sold pharmaceutical preparations marketed for cancer, old age, and retinitis pigmentosa, confirming the compound circulates in unregulated/illegal preparations as claimed. Analytical chemistry finding; says nothing about efficacy or safety. PMID 25535022
  11. Willis & Vu, 2026. Pharmacy-compounding trade-journal review discussing "Epitalon" by name alongside BPC-157, KPV, MOTS-c, Semax and TB-500 as part of a 2026 review of compounded research peptides, describing these compounds as promoted for a wide range of uses and examining concerns raised during that review. PMID 42752426
  12. US Food and Drug Administration. Briefing document for the Pharmacy Compounding Advisory Committee: epitalon (free base and acetate). July 2026. FDA media 193345
  13. FDA advisory committee backs two more peptides, rejects one for compounding list. Regulatory Affairs Professionals Society. July 2026. RAPS
Share thisFacebookXEmail